Literature DB >> 15110222

Cardiopulmonary exercise testing before and one year after mitral valve repair for severe mitral regurgitation.

Hyun-Joong Kim1, Seok Jin Ahn, Seung Woo Park, Byung Ryul Cho, Jidong Sung, Sun-Hee Hong, Pyo Won Park, Kyung Pyo Hong.   

Abstract

For the evaluation of efficacy of cardiopulmonary exercise testing, we compared New York Heart Association functional class with peak oxygen consumption rate (VO(2)peak) in 31 patients with severe mitral regurgitation who underwent mitral valve repair surgery. One year later, the VO(2)peak values did not show significant improvement; however, the patients who had more than a mild degree of residual mitral regurgitation (n = 14) after 1 year of surgery had a VO(2)peak value that was significantly decreased (from 22.7 +/- 6.4 to 21.0 +/- 6.3 ml/kg/min, p = 0.04). Patients with a higher preoperative VO(2)peak value (>/=18.5 ml/kg/min) had a significantly better New York Heart Association functional class 1 year after surgery than patients with a lower VO(2)peak value (<18.5 ml/kg/min, p = 0.03).

Entities:  

Mesh:

Year:  2004        PMID: 15110222     DOI: 10.1016/j.amjcard.2004.01.059

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  A methodology for assessing human mitral leaflet curvature using real-time 3-dimensional echocardiography.

Authors:  Liam P Ryan; Benjamin M Jackson; Thomas J Eperjesi; Theodore J Plappert; Martin St John-Sutton; Robert C Gorman; Joseph H Gorman
Journal:  J Thorac Cardiovasc Surg       Date:  2008-07-26       Impact factor: 5.209

2.  Invited commentary.

Authors:  Joseph H Gorman; Robert C Gorman
Journal:  Ann Thorac Surg       Date:  2014-05       Impact factor: 4.330

3.  The influence of annuloplasty ring geometry on mitral leaflet curvature.

Authors:  Liam P Ryan; Benjamin M Jackson; Hirotsuga Hamamoto; Thomas J Eperjesi; Theodore J Plappert; Martin St John-Sutton; Robert C Gorman; Joseph H Gorman
Journal:  Ann Thorac Surg       Date:  2008-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.